Reuters logo
2 年前
Regeneron revenue jumps 57 pct as Eylea sales surge
2015年11月4日 / 中午11点40分 / 2 年前

Regeneron revenue jumps 57 pct as Eylea sales surge

Nov 4 (Reuters) - Drugmaker Regeneron Pharmaceuticals Inc reported a 57 percent jump in quarterly revenue, powered by soaring demand for its blockbuster eye drug, Eylea.

The company's net income more than doubled to $210.4 million, or $1.82 per share, in the third quarter ended Sept. 30, from $83.4 million, or 73 cents per share, a year earlier.

The biotechnology company's total revenue jumped to $1.14 billion from $725.8 million. (Reporting by Rosmi Shaji in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below